The Motley Fool
10 Oct 2026, 22:15 UTC · 3h ago
Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?
Impact · against what's priced in
The article provides no new catalysts for Moderna or Merck, as the reported cancer vaccine progress and product portfolio expansion are already fully reflected in the current stock prices. The observation that Moderna trades 61% above analyst targets is a valuation commentary rather than a fundamental change in business prospects.
- MRK+0.00
Already priced in
- The price assumes
mRNA cancer vaccine (Intismeran) with Keytruda in melanoma and broader cancers
The positive trial results for the cancer vaccine candidate paired with Keytruda are already incorporated into the market's valuation of Merck.
What MRK's price assumes · Sep 11
Search tags
